Form 4: Day One Bio COO/CFO York's RSU Vesting & Tax Sale

Day One Biopharmaceuticals' COO and CFO, Charles N. York II, reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax liabilities.

Summary

• Charles N. York II, the Chief Operating Officer and Chief Financial Officer of Day One Biopharmaceuticals, Inc. (DAWN), reported recent transactions involving the company's common stock.
• On August 15, 2025, York acquired a total of 16,875 shares of common stock through the settlement of Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
• On August 18, 2025, York sold 4,106 shares of common stock at a weighted average price of $6.7671 per share.
• The sale was explicitly stated to be for the sole purpose of covering the Reporting Person's tax liability associated with the RSU settlement.
• Following these reported transactions, York beneficially owns 278,000 shares of Day One Biopharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation activity (RSU vesting) and a standard tax-related sale. It's generally neutral, but the continued vesting implies executive retention and alignment, which is mildly positive.

Positives

• The vesting of Restricted Stock Units indicates continued service and alignment of executive interests with shareholders.
• The acquisition of 16,875 shares through RSU settlement increases the executive's direct stake in the company.

Negatives

• The sale of 4,106 shares, even if for tax purposes, reduces the executive's direct ownership in the company.

Future Outlook

NA

Management Comments

• The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.

Industry Context

NA

Stakeholder Impact

• Shareholders: The RSU vesting and subsequent tax-related sale are routine executive compensation events, generally not indicative of a change in company fundamentals or executive confidence. The continued vesting suggests executive retention and alignment.
• Employees: Provides insight into the structure and timing of executive equity compensation.

Next Steps

• Future quarterly RSU vesting installments are scheduled for February 15, May 15, August 15, and November 15, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are common and pre-planned, not typically indicative of a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information to warrant a change in investment stance.

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Executive Compensation, Charles N. York II, COO, CFO, Biopharmaceuticals